Welcome Panthers Fans!

Check Out The All NEW & Original Carolina Panthers Den Message Board! - Many New Improvements & Features For Everyone! - New Photo Gallery Added!.... Please Register To Participate On The Forums Today! .... Updated 2007 Panthers Schedule Posted In Our Forums! .... Join Us For All The LATEST News & Discussions On Your Carolina Panthers Everyday!: Keyshawn Johnson Cut by Panthers!-Discuss on our Message Board NOW! .... Download Our NEW Panthers Den Toolbar And Get Panthers News Sent To Your Desktop! ..... Plenty Of Fun & Games: Enter Our Arcade Tournaments And Compete Against Other Forum Members! ....Try Our New Sports Bookie & Casino And Rack Up Your 'Gold Points!' .....Login To See Who Our Newest Member Of The Month Is And Find Out How YOU Can Be Our Next WINNER!!! .... We Have Something For Everyone! - Don't Miss Out On All The "Crazy Feline Fun!" At Carolina Panthers Den! - The Most "Interactive" Panthers Fansite & Message Board On The Net!!! - GUARANTEED!!!


ATB-346 targets the global dependence on a GI-secure anti-inflammatory painkiller.

John Wallace, ‘We are delighted that the planned pre-clinical research have been finished, and that these studies confirm and expand upon the extensive academic function already conducted on ATB-346. We are grateful to our partners and service providers for their assistance, which includes enabled us to carry out these studies on routine.’ Related StoriesExpanded make use of for IntelliCap with further CE Mark for aspiration of fluidsLiposomal sizing and the Coulter principle: an interview with Professor Melvin E. Klegerman CEO Dan Legault added, ‘It really is a substantial milestone for Antibe to have completed its planned pre-clinical focus on ATB-346.Had been $1.286 billion, representing a rise of 6.7 % weighed against the prior-year period, or a rise of 6.0 % on a foreign currency-neutral basis. International revenues reflected continued strength in emerging product sales and marketplaces of safety-engineered products. For the nine-month period finished June 30, 2014, revenues in the U.S. Had been $2.546 billion, representing a rise of just one 1.8 % weighed against the prior-year period. Revenues beyond the U.S. Had been $3.698 billion, representing a rise of 7.1 % in comparison to the prior-year period, or 8.1 % on a foreign currency-neutral basis.5 to 5.0 %.